foxo4 dri human trial senolytic
foxo4 dri human trial senolytic The disordered p53 transactivation domain is the target of and the compound FOXO4-DRI FOXO4-DRI Peptide Dosing Guide: Senolytic
FOXO4 DRI Peptide Dosing Guide: Senolytic Peptide Protocol (June 2026) FOXO4 DRI 10mg vial Description RCpeptides Emerging strategies in senotherapeutics: from broad spectrum senolysis to precision reprogramming npj Aging FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine
USD25.90
USD68.90
Pay in 4 interest-free payments of $6.47 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
